Interpretation of critical update： AASLD practice guidance on prevention， diagnosis， and treatment of hepatocellular carcinoma
- VernacularTitle:《2025年美国肝病学会实践指导： 肝细胞癌的预防、诊断和治疗（关键更新）》解读
- Author:
Yuze ZHAO
1
;
Yuxiao CHEN
1
;
Kechun WANG
1
;
Mingda WANG
1
;
Tian YANG
1
Author Information
- Publication Type:Journal Article
- Keywords: Carcinoma， Hepatocellular; Prevention; Diagnosis; Therapeutics; United States; Consensus
- From: Journal of Clinical Hepatology 2025;41(5):851-854
- CountryChina
- Language:Chinese
- Abstract: In February 2025， the American Association for the Study of Liver Diseases （AASLD） published online “Critical Update： AASLD Practice Guidance on Prevention， Diagnosis， and Treatment of Hepatocellular Carcinoma”. This update mainly focuses on the latest analysis results of the IMbrave050 study and performs corresponding updates and adjustments to recommendations based on the issues in clinical practice. As for the postoperative adjuvant therapeutic strategies for hepatocellular carcinoma （HCC） based on immune checkpoint inhibitors， the AASLD has re-evaluated and updated the practice guidance. The update revises related texts and recommendations for adjuvant therapy and the management algorithms for HCC recurrence during or after adjuvant therapy. Furthermore， the AASLD emphasizes that even for HCC patients at a high risk of recurrence after resection or local ablation， close monitoring for recurrence remains the current standard treatment regimen. Our team makes an excerpt of the update， systematically introduces the background and specific contents of the update， and discuss the adjuvant therapy for HCC， in order to provide a reference for readers.
